Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

Annual Report to shareholders

Monday, September 30, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has made significant advancements, including the initiation of a Phase 1/2a clinical study for BetaBart (RV-01) and receiving IND approval from the US FDA. The company has also reported positive clinical updates across four programs, indicating a strong pipeline and commitment to innovation. These developments are promising for shareholders and the company's future.

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has initiated a Phase 1/2a clinical study.
  • The company received IND approval from the US FDA.
  • Positive clinical updates were provided across four programs.

Full Press Release Details

• Announcements
• Periodic Reports
• September 30, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• June 25, 2024
• Announcements
• August 23, 2024
• Announcements
• November 15, 2023
• Announcements
• March 27, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What recent clinical study did Radiopharm Theranostics initiate?

Radiopharm Theranostics initiated a Phase 1/2a clinical study for BetaBart (RV-01).

What approval did Radiopharm receive from the FDA?

The company received IND approval from the US FDA to initiate a therapeutic clinical study.

How many programs received positive clinical updates?

Radiopharm provided positive clinical updates across four programs.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics BetaBart Phase 1/2a FDA IND approval clinical updates
Last updated: Sep 30, 2024